Investor Alert

New York Markets Open in:

Market Pulse Archives

March 21, 2019, 7:41 a.m. EDT

Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinued

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Biogen Inc. (BIIB)
  • X
    Eisai Co. Ltd. (4523)
  • X
    Eisai Co. Ltd. ADR (ESALY)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Shares of Biogen Inc. /zigman2/quotes/201531540/composite BIIB -1.60% plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. /zigman2/quotes/203064480/delayed JP:4523 +2.74% /zigman2/quotes/202565502/composite ESALY +0.71% said Thursday they have decided to discontinue late-stage trials of a treatment for Alzheimer's disease, after an independent data monitoring committee said they were unlikely to meet its primary goal. The phase 3 trials sought to evaluate the efficacy and saftey of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. "This disappointing news confirms the complexity of treating Alzheimer's disease and the need to further advance knowledge in neuroscience," Biogen Chief Executive Michael Vounatsos said in a statement. The companies are planning to present detailed data from the trials at future medical meetings to help with ongoing research. A phase 2 safety study and a phase 1b study will also be discontinued. Aducanumab is an investigational compound being studied for treatment in early Alzheimer's. Biogen shares were on track to open at the lowest level seen during regular-session hours since July 2016. The stock has gained 15.6% over the past 12 months through Wednesday, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.20% has advanced 4.1%.

/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 288.54
-4.68 -1.60%
Volume: 905,514
Aug. 13, 2020 4:00p
P/E Ratio
8.45
Dividend Yield
N/A
Market Cap
$46.42 billion
Rev. per Employee
$1.55M
loading...
/zigman2/quotes/203064480/delayed
JP : Japan: Tokyo
¥ 9,671.00
+258.00 +2.74%
Volume: 1.06M
Aug. 14, 2020 3:00p
P/E Ratio
22.26
Dividend Yield
1.65%
Market Cap
¥2663.71 billion
Rev. per Employee
¥60.00M
loading...
/zigman2/quotes/202565502/composite
US : U.S.: OTC
$ 87.75
+0.62 +0.71%
Volume: 1,839
Aug. 13, 2020 3:04p
P/E Ratio
21.92
Dividend Yield
1.42%
Market Cap
$24.92 billion
Rev. per Employee
$543,512
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,373.43
-6.92 -0.20%
Volume: 1.96B
Aug. 13, 2020 5:10p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.